ABSTRACT Although the bipyridine agent amrinone is reported to have a positive inotropic effect on the left ventricle, the effect of this drug on right ventricular contractility in the clinical setting is unknown. We studied the effect of short-term intravenous administration of amrinone on right ventricular systolic function in nine patients with severe congestive heart failure and, using radionuclide ventriculography, examined the right ventricular end-systolic pressure-volume relationship to determine whether reduced right ventricular afterload or increased contractility predominantly accounted for the observed improvement in right ventricular systolic function. In each patient the right ventricular end-systolic pressure-volume relationship was derived with use of varying doses of nitroprusside. After nitroprusside was stopped, intravenous amrinone (3 mg/kg) caused decreases from baseline in pulmonary arterial end-systolic pressure in eight of nine patients (23 ± 11% [overall mean ± SE], p < .05), and in pulmonary vascular resistance in all patients (38 ± 6%, p < .001). Right ventricular endsystolic volume decreased (23 8%, p < .01) and right ventricular ejection fraction increased (31 ± 10%, p = .01). The amrinone-induced decrease in right ventricular end-systolic volume was compared with that predicted for right ventricular afterload reduction alone based on the effect of amrinone on pulmonary arterial end-systolic pressure and the pressure-volume relationship observed during infusion of nitroprusside. With amrinone, a trend was observed toward a shift in the right ventricular endsystolic pressure-volume relationship in seven of nine patients; however, for the group as a whole, the observed effect of amrinone was not significantly different from that predicted from the degree of right ventricular afterload reduction. In conclusion, in patients with severe congestive heart failure, amrinone decreases right ventricular afterload, reduces right ventricular end-systolic volume, and increases right ventricular ejection fraction. The effect of amrinone on right ventricular systolic function results predominantly from right ventricular afterload reduction. 
THE BIPYRIDINE COMPOUND amrinone has been shown to have both inotropic and vasodilator actions in isolated tissue preparations' and to improve hemodynamics in patients with congestive heart failure. 4 '3 Examination of both isovolumetric phase contractile indexes4 and ventricular end-systolic pressure-volume relationships'3 have indicated that at least some of the hemodynamic responses observed in man during the infusion of amrinone may be attributed to augmented left ventricular inotropic state.
The effect of amrinone on the right ventricle has not been extensively studied and its effect on right ventricular contractility has not been demonstrated. In patients with congestive heart failure, amrinone reduces pulmonary arterial pressure,4'5 presumably due to combined effects on left ventricular contractility and systemic and pulmonary vascular tone. The resulting diminution in right ventricular afterload would be expected to improve right ventricular systolic performance. The extent to which augmented contractility of the thin-walled right ventricle contributes to improved right ventricular ejection during the infusion of amrinone is unknown.
Using radionuclide ventriculography in patients with congestive heart failure, we have previously demonstrated a linear relationship between pulmonary arterial end-systolic pressure and right ventricular endsystolic volume during administration of vasodilators that is analogous to the left ventricular end-systolic pressure-volume relationship. 14' 15 In the present study, we compared the effects of intravenous amrinone and nitroprusside, examining right ventricular end-systolic pressure-volume relationships to test the hypothesis that the amrinone-induced decrease in right ventricular end-systolic volume exceeds that predicted for right ventricular afterload reduction, indicating a significant inotropic effect.
Methods
The study population consisted of nine patients, six men and three women, ranging in age from 26 to 72 (mean 59) years. All were in New York Heart Association functional class Ill or IV. Four patients had congestive cardiomyopathy, and five patients had coronary artery disease with healed myocardial infarcts. All gave written informed consent.
Study protocol. All frame. Activity in 5 ml heparinized blood samples, drawn at the midpoint of each scan acquisition, was counted with the same gamma camera and collimator as were used for cardiac imaging, and counts were corrected for decay occurring between the times of cardiac and blood sample scan acquisitions. Changes in end-diastolic and end-systolic volumes compared with baseline were calculated as fractional changes in the ratios of ventricular counts per second to decay-corrected blood counts per second at end-diastole and end-systole, respectively. 14, 15 18 We have validated our method for quantifying right ventricular function in patients with right ventricular pressure overload, volume overload, and/or depressed systolic function. '9 Intraobserver variability of our radionuclide measurements has been tested by analysis of duplicate scans with duplicate blood sample acquisitions in a series of 10 patients. Coefficients of variation for right ventricular end-diastolic volume, end-systolic volume, and ejection fraction were 5.1%, 4.9%, and 3.3% (percent of measured ejection fraction), respectively.
Statistical methods. We compared baseline hemodynamic and radionuclide measurements with those obtained after drug administration using paired t tests. We evaluated the relationship between nitroprusside-induced changes in pressure and volume in each individual using linear regression analysis. PAES = pulmonary arterial end-systolic; PAPS = pulmonary arterial peak systolic; PCW = pulmonary capillary wedge; PVR = pulmonary vascular resistance; RA = right atrial; RVEDV = right ventricular end-diastolic volume; RVEF = right ventricular ejection fraction; RVESV = right ventricular end-systolic volume.
Ap < .05 vs baseline; Bp < .01 vs baseline.
Results
The effects of nitroprusside and amrinone on hemodynamic and radionuclide measurements are listed in table 1. Neither drug significantly altered resting heart rate. Both nitroprusside (p < .005) and amrinone (p < .005) significantly reduced mean arterial pressure. Both drugs significantly decreased mean pulmonary capillary wedge pressure (p < .01) and mean right atrial pressure (p < .001). Pulmonary arterial endsystolic pressure decreased in all patients during administration of nitroprusside (p < .001) and in eight of nine patients after amrinone (p < .05), with no significant difference between the effects of the two drugs (figure 1). Pulmonary arterial peak systolic pressure was likewise reduced by both nitroprusside (p < .001) and amrinone (p < .05). Both drugs significantly increased cardiac output (p < .001) and decreased pulmonary vascular resistance (p < .001; figure 1 ). Both nitroprusside and amrinone significantly reduced right ventricular end-diastolic (p < .01 and p < .05, respectively) and end-systolic (p < .01) volumes (figure 2). Baseline right ventricular ejection fraction varied widely from 0.14 to 0.58 (mean 0.32 ± 0.15 [SD] ) and increased to a similar degree after nitroprusside (p < .01) and amrinone (p = .01; figure 2) .
To test the hypothesis that the effect of amrinone on right ventricular end-systolic volume exceeded that predicted from the reduction in right ventricular afterload, we first examined the relationship between nitroprusside-induced changes in end-systolic pressure and volume in each patient ( figure 3) . The decrease in endsystolic volume expected with amrinone based only on Vol. 74, No. 2, August 1986 right ventricular afterload reduction was then estimated from individual nitroprusside-derived right ventricular end-systolic pressure-volume slopes and from the amrinone-induced fractional reduction in pulmonary arterial end-systolic pressure. The observed effect exceeded that predicted to result from afterload reduction in seven of nine patients, although there was no significant difference between mean predicted and observed effects (figure 4). For the entire patient group combined, the average fractional change in pulmonary arterial end-systolic or peak systolic pressure was plotted against the average fractional change in right ventricular end-systolic volume induced by both nitroprusside and amrinone (figure 5). The amrinone data points were not significantly displaced from the regression lines derived from nitroprusside data, indicating that the overall effect of amrinone on end-systolic volume could be explained predominantly on the basis of right ventricular afterload reduction.
Discussion
The bipyridine amrinone has been shown to have cardiac inotropic effects in isolated tissue prepara- RV END-SYSTOLIC VOLUME (/ of Baseline) tients, we first constructed individual right ventricular end-systolic pressure-volume relationships using various doses of nitroprusside and then determined whether the effect of amrinone on right ventricular endsystolic volume differed significantly from that observed with nitroprusside for the degree of reduction in pulmonary arterial end-systolic pressure. We observed an amrinone-induced decrease in right ventricular afterload in all but one patient, and this effect was the predominant factor responsible for the improvement in right ventricular systolic function. Compared with our previous findings for the left ventricle, the lesser evidence for a right ventricular inotropic effect is likely to be related to differences in myocardial mass of the two ventricles and to the fact that systolic function is more strongly dependent on changes in afterload for the right ventricle than for the left ventricle.15 Several prior studies have demonstrated the strong link between pulmonary arterial pressure 100 end-systolic pressure and volume and compared them with the effects of nitroprusside to identify the predominant mechanism for amrinone's improvement of right ventricular systolic function. In the isolated canine right ventricle, Maughan et al. 34 have demonstrated that the right ventricular end-systolic pressure-volume relationship is analogous to that observed for the left ventricle, with the slope similarly responsive to acute changes in contractility. Using pulmonary artery dicrotic notch pressure and radionuclide-derived estimates of changes in right ventricular end-systolic volume, we have previously observed that the characteristics of the right ventricular end-systolic pressure-volume relationship during administration of vasodilators in patients with congestive heart failure are similar to those of the left ventricular relationship; there is linearity within a physiologic range of afterload alteration and correlation between the pressurevolume slope and other parameters of systolic performance. 4 analogous to that observed in the left ventricle, although with shallower pressure-volume slopes.'4' '5 Measurement of absolute right ventricular volumes was not necessary for the purpose of our analysis, in which the effects of amrinone and nitroprusside were compared and each patient served as his own control.
The potential effect of tricuspid regurgitation in some patients on the accuracy of our measurements should be considered. Thermodilution cardiac output measurements have been widely used in similar populations to determine the general effect of pharmacologic interventions,5' 7 9 1 12,37 although in individual patients the presence of tricuspid regurgitation may reduce the accuracy of this technique. Our conclusions regarding the relative inotropic vs afterload-reducing effects of amrinone on the right ventricle are based on pressure and radionuclide volumetric measurements, rather than on thermodilution cardiac output. In similar populations, any tricuspid regurgitation that may have been present did not appear to adversely affect the accuracy of radionuclide right ventricular measurements'9 or to alter the expected characteristics of the right ventricular end-systolic pressure-volume relationship.'4' 15 Furthermore, experimental evidence indicates no effect of acute changes in right ventricular diastolic load on the end-systolic pressure-volume relationship. 34 Right ventricular afterload would be more closely approximated by ventricular systolic stress than by end-systolic volume. However, the complex shape of the right ventricle and difficulty in estimating chamber dimension and wall thickness by presently available techniques render the ability to measure right ventricular wall stress questionable in the clinical setting. We therefore approximated acute drug-induced changes in right ventricular afterload from changes in pulmonary arterial dicrotic notch pressure using methodology analogous to that which has been widely used for the left ventricle2022 2931 and which we14' 15 and others23 have previously described for the right ventricle.
Because of the long plasma half-life of amrinone (3 to 15 hr),41 it was not practically feasible to randomize the order of drug administration, and the possibility of a carryover of hemodynamic effects from nitroprusside must be considered. However, the duration of effect after cessation of nitroprusside is short, and the persistence of rebound hemodynamic effects into the period of amrinone infusion was minimized because hemodynamics were allowed to return to a steady-state baseline level before amrinone was initiated. There was no observed difference between initial and repeat (postnitroprusside) baseline hemodynamics.
Our findings should not be construed to indicate that amrinone never exerts inotropic effects on the right ventricle. After administration of amrinone, some right ventricular inotropic effect was suggested in the majority of our patients by a decrease in end-systolic volume beyond that expected for the degree of afterload reduction, although this effect was not statistically significant. The magnitude of any change in right ventricular contractility was small in its contribution to the observed improvement in systolic performance, which resulted predominantly from the amrinone-induced reduction in right ventricular afterload. However, we studied only patients with severe left ventricular failure due to either coronary artery disease or cardiomyopathy. It is possible that patients with greater degrees of right ventricular hypertrophy related to cor pulmonale, primary pulmonary hypertension, or valvular or congenital heart disease would manifest more evidence of an amrinone-induced right ventricular inotropic effect.
